These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2019 related items for PubMed ID: 25306226

  • 21. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM, Koochekpour S.
    Oncotarget; 2016 Sep 27; 7(39):64447-64470. PubMed ID: 27487144
    [Abstract] [Full Text] [Related]

  • 22. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L, Tien JC, Vo J, Tan M, Parolia A, Zhang Y, Wang L, Qiao Y, Shukla S, Wang X, Zheng H, Su F, Jing X, Luo E, Delekta A, Juckette KM, Xu A, Cao X, Alva AS, Kim Y, MacLeod AR, Chinnaiyan AM.
    Cancer Res; 2018 Oct 15; 78(20):5731-5740. PubMed ID: 30135193
    [Abstract] [Full Text] [Related]

  • 23. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
    Ho Y, Dehm SM.
    Endocrinology; 2017 Jun 01; 158(6):1533-1542. PubMed ID: 28368512
    [Abstract] [Full Text] [Related]

  • 24. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ.
    Eur Urol; 2015 Jan 01; 67(1):53-60. PubMed ID: 24882673
    [Abstract] [Full Text] [Related]

  • 25. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ, Chou FJ, Li L, Lin CY, Yeh S, Chang C.
    Cancer Lett; 2017 Jul 10; 398():62-69. PubMed ID: 28373004
    [Abstract] [Full Text] [Related]

  • 26. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.
    Cancer Lett; 2017 Jul 01; 397():133-143. PubMed ID: 28323036
    [Abstract] [Full Text] [Related]

  • 27. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J, Fitzpatrick JM.
    BJU Int; 2016 Feb 01; 117(2):215-25. PubMed ID: 25818596
    [Abstract] [Full Text] [Related]

  • 28. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
    Liu C, Armstrong C, Zhu Y, Lou W, Gao AC.
    Oncotarget; 2016 May 31; 7(22):32210-20. PubMed ID: 27049719
    [Abstract] [Full Text] [Related]

  • 29. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, Steinestel J.
    Eur Urol; 2017 Jan 31; 71(1):1-3. PubMed ID: 27471164
    [Abstract] [Full Text] [Related]

  • 30. Emerging mechanisms of enzalutamide resistance in prostate cancer.
    Claessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, Van Poppel H, Joniau S.
    Nat Rev Urol; 2014 Dec 31; 11(12):712-6. PubMed ID: 25224448
    [Abstract] [Full Text] [Related]

  • 31. Persistent androgen receptor addiction in castration-resistant prostate cancer.
    Schweizer MT, Yu EY.
    J Hematol Oncol; 2015 Nov 13; 8():128. PubMed ID: 26566796
    [Abstract] [Full Text] [Related]

  • 32. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J, Taylor AR, Divine GW, Hafron JM, Hwang C.
    Clin Genitourin Cancer; 2016 Oct 13; 14(5):381-388. PubMed ID: 27157640
    [Abstract] [Full Text] [Related]

  • 33. ARN-509: a novel antiandrogen for prostate cancer treatment.
    Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.
    Cancer Res; 2012 Mar 15; 72(6):1494-503. PubMed ID: 22266222
    [Abstract] [Full Text] [Related]

  • 34. Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis.
    Fan A, Li Y, Zhang Y, Meng W, Pan W, Chen M, Ma Z, Chen W.
    Apoptosis; 2024 Oct 15; 29(9-10):1679-1695. PubMed ID: 38478171
    [Abstract] [Full Text] [Related]

  • 35. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q, Song Z, Ruan H, Wang C, Yang X, Bao L, Wang K, Cheng G, Xu T, Xiao W, Xiong Z, Liu D, Yang M, Zhou D, Yang H, Chen K, Zhang X.
    Clin Cancer Res; 2020 Mar 15; 26(6):1516-1528. PubMed ID: 31796514
    [Abstract] [Full Text] [Related]

  • 36. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
    Penning TM.
    J Steroid Biochem Mol Biol; 2015 Sep 15; 153():105-13. PubMed ID: 26032458
    [Abstract] [Full Text] [Related]

  • 37. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.
    Semenas J, Dizeyi N, Persson JL.
    Drug Des Devel Ther; 2013 Sep 15; 7():875-81. PubMed ID: 24009414
    [Abstract] [Full Text] [Related]

  • 38. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M, Huang Y, Ratnam M.
    Biochem Biophys Res Commun; 2016 Jul 22; 476(2):69-74. PubMed ID: 27179779
    [Abstract] [Full Text] [Related]

  • 39. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, de Wit R, van Weerden WM.
    Eur Urol; 2015 Jun 22; 67(6):981-985. PubMed ID: 25484141
    [Abstract] [Full Text] [Related]

  • 40. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
    Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO.
    Cancer; 2018 Mar 15; 124(6):1216-1224. PubMed ID: 29266182
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 101.